Medical Cannabis Use in Autism: Insights from an Israeli HMO on Patient Characteristics and Alignment with National Guidelines
Medical cannabis use among autistic individuals was rare and mainly observed among those with more complex clinical profiles and higher socioeconomic backgrounds. Most prescriptions did not fully comply with guidelines requiring prior antipsychotic trials. These findings underscore the need for enhanced regulatory oversight, equitable access, and longitudinal research to evaluate real-world outcomes and guide evidence-based clinical practice.
Authors
- Ronen Arbel (ORCID: https://orcid.org/0000-0002-6058-8665)
- Gal Meiri (ORCID: https://orcid.org/0000-0003-4100-4588)
- Hadar Sadeh
- Doron Netzer (ORCID: https://orcid.org/0009-0000-0466-7310)
- Talish Razi (ORCID: https://orcid.org/0009-0006-2172-1044)
Institutions
- Ben-Gurion University of the Negev (IL)
- Sapir College (IL)
- Soroka Medical Center (IL)
- Ariel University (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Journal of Child and Adolescent Psychopharmacology
- Published
- 2025-12-03
- DOI
- https://doi.org/10.1177/10445463251404404
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00